Compare Gartner Inc (IT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Mesoblast Limited — how do they compare? Gartner Inc trades at $139.51 (market cap $9.44B), while Mesoblast Limited trades at $16.08 (market cap $2.17B). The key difference: Gartner Inc is far larger — about 4.4× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| IT | MESO | |
|---|---|---|
Market Cap | $9.44B | $2.17B |
Sector | Technology | Technology |
52-Week High | $357.98 | $20.96 |
52-Week Low | $125.68 | $12.88 |
Enterprise Value | $11.04B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
